Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Part D coverage for obesity medications is expected to begin in January 2027 under the CMS BALANCE Model, with eligible beneficiaries paying $50/month
"The potential disadvantage for both the oral Wegovy and the oral Rhapsido is that you then do go to daily dosing," Guidry said
Discontinuation rates of 12-18% due to adverse events
Patients should follow the Instructions for Use, injecting subcutaneously at a 90 angle into the abdomen, thigh, or upper arm
Monitoring and follow-up should be arranged at 3 months initially to assess HbA1c response, tolerability, weight change, blood pressure, and renal function
US$ 29.78
US$ 22.99
US$ 27.50
US$ 25.65
